{
    "clinical_study": {
        "@rank": "31597", 
        "arm_group": [
            {
                "arm_group_label": "Treated Thigh", 
                "arm_group_type": "Experimental", 
                "description": "Trusculpt (Radio Frequency) Device"
            }, 
            {
                "arm_group_label": "Untreated Contra-lateral Thigh", 
                "arm_group_type": "No Intervention", 
                "description": "To be used as the self control in this split body study."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the safety and efficacy of the  Trusculpt (Radio\n      Frequency) device in the reduction of thigh circumference."
        }, 
        "brief_title": "The Trusculpt (Radio Frequency) Device For Thigh Circumference Reduction", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Localized Unwanted Fat Bulges (Subcutaneous Adipose Tissue)", 
        "detailed_description": {
            "textblock": "The primary efficacy variable for this study is the comparison of mean change in thigh\n      circumference from baseline to 12 weeks between two arms. The primary research hypothesis is\n      that the mean change in thigh circumference is \u2265 1 cm (indicating mean reduction)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female\n\n          -  Minimum age of 18 years\n\n          -  Non-smoking for at least 3 months and willing to refrain from smoking for the\n             duration of the study.\n\n          -  Post-menopausal, or on birth control and/or no plans to become pregnant for the\n             duration of the study.\n\n          -  Body Mass Index (BMI) \u2264 30\n\n          -  Visible fat in the thigh / saddlebag area to be treated\n\n          -  Subject must be able to read, understand and sign the Consent Form\n\n          -  Subject must adhere to the follow-up schedule and study instructions\n\n          -  Subject must adhere to the same diet and/or exercise routine throughout the study,\n             and agree to maintain the same weight throughout the study (within 6 lbs of the\n             weight measure at the baseline assessment)\n\n        Exclusion Criteria:\n\n          -  Taking weight-loss medications/supplements\n\n          -  Simultaneous participation in any other clinical study\n\n          -  Prior surgical treatment to the target area, e.g., liposuction or abdominoplasty\n\n          -  Prior treatment to the target area within the last 12 months e.g., radio frequency or\n             cryolysis\n\n          -  Arteriosclerosis or weakened blood vessels\n\n          -  Heart disease\n\n          -  Thromboembolic disease\n\n          -  Diagnosed or documented immune system disorders (including Panniculitis)\n\n          -  Bleeding disorders\n\n          -  Presence of uncontrolled hypertension\n\n          -  Taking prescription anticoagulants\n\n          -  History of keloid formation\n\n          -  History of malignant tumors in the target area\n\n          -  Diabetes\n\n          -  Any disease or condition that could impair wound healing\n\n          -  Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large\n             moles\n\n          -  Infection in the target area\n\n          -  Implanted electrical device(s) or metallic implants\n\n          -  Pregnant or lactating"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665118", 
            "org_study_id": "C-12-TS05"
        }, 
        "intervention": {
            "arm_group_label": "Treated Thigh", 
            "intervention_name": "Trusculpt (Radio Frequency) Device", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Radio frequency", 
            "thigh", 
            "circumference", 
            "reduction"
        ], 
        "lastchanged_date": "August 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94005"
                    }, 
                    "name": "Cutera Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montclair", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07042"
                    }, 
                    "name": "New Jersey Plastic Surgery"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Nashville Center for Laser and Facial Surgery"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Cutera Trusculpt Device For Thigh Circumference Reduction", 
        "overall_official": [
            {
                "last_name": "Brian Biesman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "last_name": "Barry DiBernardo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "last_name": "Stephen Ronan, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in thigh circumference from baseline compared to the non-treated contra-lateral side", 
            "safety_issue": "No", 
            "time_frame": "At 12 weeks post- final treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665118"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Numeric Verbal Scale (0-10)", 
                "measure": "Subject discomfort and pain levels", 
                "safety_issue": "Yes", 
                "time_frame": "During treatment, 4 and 12 weeks post- final treatment"
            }, 
            {
                "measure": "Subject Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "At 4 and 12 weeks post- final treatment."
            }, 
            {
                "measure": "Subject's Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "At 4 and 12 weeks post- final treatment"
            }, 
            {
                "measure": "Physician's Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "At 4 and 12 weeks post- final treatment"
            }, 
            {
                "measure": "Incidence and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "source": "Cutera Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cutera Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}